[{"from": "human", "value": "Provide a description of this molecule. [C][C][C][C][C][Branch2][=Branch1][O][C][N][Branch2][Branch1][=C][C][=C][C][=Branch2][Branch1][=Branch1][=C][Branch1][#C][C][=C][Ring1][=Branch1][S][=Branch1][C][=O][=Branch1][C][=O][N][Ring1][=N][O][C][C][=Branch1][C][=O][N][C@H1][Branch1][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=Branch1][C][=O][N][C@@H1][Branch1][Ring1][C][C][C][=Branch1][C][=O][O][S][C][C][=C][C][=C][C][=C][Ring1][=Branch1][C][C][C][C]"}, {"from": "gpt", "value": "The molecule is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familiar intrahepatic cholestasis (PFIC). Odevixibat is the first approved non-surgical treatment option for PFIC. Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].  Odevixibat was granted FDA approval on 20 July 2021."}]